PathAI Review

PathAI is a Boston-based company that develops AI-powered software for digital pathology. Its platform is designed to help pathologists and researchers analyze whole-slide images of tissue samples with greater speed and consistency. By applying machine learning models trained on large datasets of annotated pathology images, PathAI aims to reduce diagnostic variability and improve the accuracy of disease detection and grading. The platform serves two primary markets: biopharma and clinical pathology. For pharmaceutical and biotechnology companies, PathAI offers tools to support companion diagnostics development, clinical trial patient selection, and biomarker quantification. These capabilities are intended to help drug developers better stratify patient populations and evaluate treatment responses in oncology and other disease areas. On the clinical side, PathAI offers products under the AISight brand, which is a digital pathology ecosystem designed for clinical laboratories transitioning to digital workflows. This includes image management, quality control tools, and AI-assisted analysis integrated into the pathologist's review process. PathAI's models cover a range of disease areas including oncology, liver disease, and infectious diseases. The company develops these models in collaboration with academic medical centers and industry partners, building disease-specific algorithms that are validated against pathologist consensus annotations. PathAI operates primarily as an enterprise solution, working with large pharmaceutical companies, contract research organizations, and hospital laboratory systems. Pricing and access are managed through direct commercial agreements, and the platform is not offered as a self-service consumer product.